University of Groningen Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma Pavlov,

[1]  R. Pfeiffer,et al.  MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[2]  P. Siersema,et al.  Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma , 2015, Journal of Gastroenterology.

[3]  Jin-lin Wu,et al.  miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment. , 2014, The American journal of pathology.

[4]  M. Borrello,et al.  miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma , 2014, Oncotarget.

[5]  G. Calin,et al.  Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.

[6]  M. Wallace,et al.  Survival in esophageal high-grade dysplasia/adenocarcinoma post endoscopic resection. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  Dongdi Wu,et al.  MicroRNA-199a-3p Regulates Endometrial Cancer Cell Proliferation by Targeting Mammalian Target of Rapamycin (mTOR) , 2013, International Journal of Gynecologic Cancer.

[8]  E. Montgomery,et al.  microRNA 223 Is Upregulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1 , 2013, Clinical Cancer Research.

[9]  J. Yélamos,et al.  Predictive Value of MicroRNAs in the Progression of Barrett Esophagus to Adenocarcinoma in a Long-Term Follow-up Study , 2013, Annals of surgery.

[10]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[11]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[12]  E. Kroh,et al.  Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies , 2011, Cancer Prevention Research.

[13]  M. Albitar,et al.  Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma , 2011, Journal of clinical gastroenterology.

[14]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[15]  A. Tsykin,et al.  MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma , 2010, The British journal of surgery.

[16]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[17]  Kenneth K Wang,et al.  MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma , 2009, Clinical Cancer Research.

[18]  Andrew Feber,et al.  MicroRNA expression profiles of esophageal cancer. , 2008, The Journal of thoracic and cardiovascular surgery.

[19]  H. Sue-Ling,et al.  Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer , 2004, The British journal of surgery.

[20]  D. Ransohoff,et al.  Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. , 2002, JAMA.

[21]  Noel S Weiss,et al.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.

[22]  A. van den Berg,et al.  Studying microRNAs in lymphoma. , 2013, Methods in molecular biology.

[23]  S. Spechler,et al.  Barrett's esophagus. , 1994, Seminars in oncology.